Skip to main content
Psych Congress  

Deutetrabenazine Is Associated With an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia (TD) as Seen by the High Proportion of Responders to Treatment in the ARM-TD Study

Joohi Jimenez-Shahed, MD; Stewart A. Factor, DO; William Ondo, MD; Mat D. Davis, PhD; David Stamler, MD; Robert A. Hauser, MD, MBA; Hubert H. Fernandez, MD
Teva Pharmaceutical Industries Ltd

This poster was presented at the 29th Annual U.S. Psychiatric & Mental Health Congress, held October 21-24, 2016, in San Antonio, Texas.

Introduction: TD is an involuntary movement disorder with a high unmet need; there are no FDA-approved treatments to date. In ARM-TD, deutetrabenazine, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, reduced overall Abnormal Involuntary Movement Scale (AIMS) score compared with placebo (-3.0 vs -1.6, P=0.0188; primary endpoint) in patients with moderate to severe TD, and was well tolerated.
Objective: To examine response rates between deutetrabenazine-treated patients and placebo; responders achieved pre-specified response levels from 10-90% improvement on AIMS from baseline in 10% increments.
Methods: Patients were randomized (1:1) to 12 weeks' treatment with deutetrabenazine or placebo. AlMS score was assessed by blinded central video rating. Cumulative proportion (10-90% improvement) of AIMS responders from baseline to Week 12 was a secondary endpoint. Results reported include TD patients with baseline AIMS score ≥6, the intended study population.
Results: For all assessable response levels, deutetrabenazine-treated patients (n=48) had higher odds of being a responder compared with placebo (n=49) (odds ratio [OR] >1). More patients treated with deutetrabenazine were responders versus placebo at ≥10% (77.1% vs 44.9%; OR:4.1), ≥20% (54.2% vs 30.6%; OR:2.7), ≥30% (50.0% vs 26.5%; OR:2.8), ≥40% (33.3% vs 24.5%; OR:1.5), ≥50% (25.0% vs 18.4%; OR:1.5), ≥60% (20.8% vs 8.2%; OR: 3.0), ≥70% (10.4% vs 0%; OR: NA), ≥80% (8.3% vs 0%; OR: NA), and ≥90% (2.1% vs 0%; OR: NA) response levels.
Conclusions: In ARM-TD, a higher proportion of deutetrabenazine patients were responders compared with placebo, defined by percent improvement on AIMS from baseline to Week 12.    

Back to Top